Grace Therapeutics financials
$2.11−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$11.1M | -$16.7M |
| Net income | -$7.8M | -$9.6M |
| Net margin | — | — |
| Diluted EPS | $-0.47 | $-0.79 |
| EBITDA | -$11.1M | -$16.7M |
| Operating cash flow | -$8.9M | -$14.9M |
| Free cash flow | -$8.9M | -$14.9M |
| Diluted shares | 16.5M | 12.1M |
Balance sheet
| Period end | Mar 31 | Mar 31 |
|---|---|---|
| Cash & equivalents | $17.0M | $22.1M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $66.7M | $72.0M |
| Total liabilities | $2.8M | $5.4M |
| Shareholders' equity | $63.9M | $66.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology